Advancing Monoclonal Antibody Innovation and Pandemic Preparedness

Becker’s Healthcare Podcast | Released July 17, 2025
Guest: Mark Alia, Chairperson of the Board at Invivyd
Host: Erica Carbajal

Introduction

In this episode of the Becker’s Healthcare Podcast, Erica Carbajal engages in a profound conversation with Mark Alia, the Chairperson of the Board at Invivyd. The discussion delves into the evolution of monoclonal antibody technology, pandemic preparedness, and the personal and professional journey of Mark Alia amidst the COVID-19 pandemic.

Mark Alia’s Personal Journey and Role at Invivyd

Mark Alia begins by sharing his extensive background in the biotech and finance industries, highlighting his transition to founding an investment firm in 2019 focused on biotechnology. His foresight led him to invest in Invivyd during the early months of the COVID-19 pandemic, recognizing the potential and challenges of developing monoclonal antibodies for SARS-CoV-2.

Mark Alia [00:41]: “At around the year 2019, I decided to start my own investment firm... and there was this mysterious pneumonia making its way across mainland China.”

Alia recounts his personal battle with COVID-19 in November 2021, detailing a severe case that led to hospitalization and ongoing struggles with Long COVID. This personal experience reinforced his commitment to advancing Invivyd’s mission to address both acute and long-term effects of COVID-19.

Mark Alia [02:05]: “I woke up pretty certain I was dying... I have some measure of ongoing autonomic dysfunction... post exertional malaise.”

His return to Invivyd’s board marked a pivotal shift towards developing sustainable solutions for endemic SARS-CoV-2, emphasizing the need for continuous innovation in antibody therapies.

Invivyd’s Technology Platform and Monoclonal Antibodies

The conversation shifts to Invivyd’s unique approach to monoclonal antibody (mAb) development. Unlike traditional pharmaceutical mAbs targeting self-antigens, Invivyd focuses on immunorecessive epitopes—areas less likely to provoke an immune response—ensuring greater stability and efficacy.

Mark Alia [05:13]: “Our epitope is pretty quiet, it doesn't move a lot, which is critical, right...”

Alia explains their method of directed mutagenesis to refine antibody binding, fostering innovation through a synthetic approach. He underscores the importance of collaboration with the FDA to iterate antibodies, akin to how vaccines are regularly updated to match circulating strains.

Mark Alia [06:30]: “We are very comfortable as a society iterating vaccine antigens... we're looking to iterate antibodies in a similar rational manner.”

Addressing Infectious Diseases and Pandemic Preparedness

Mark Alia emphasizes the critical role of monoclonal antibodies in bridging the gaps left by vaccines, especially for vulnerable populations. He highlights the complementary nature of vaccines and passive prophylaxis in managing infectious diseases.

Mark Alia [07:52]: “You can't beat a good vaccine... there's an opportunity... to augment passive prophylaxis or so-called antibody use.”

Alia advocates for scaling antibody technologies to provide widespread protection, moving beyond niche products to democratize access and enhance societal resilience against both current and emerging pathogens.

Mark Alia [08:30]: “We're just laser focused on getting as many people the maximum benefit our technology allows.”

The Patient Voice and Regulatory Evolution

The discussion transitions to the evolving landscape of regulatory processes, with a growing emphasis on incorporating patient perspectives. Alia notes the increased advocacy for patient-informed decision-making within the FDA framework.

Mark Alia [09:55]: “Highly informed patients... reflecting the wishes of an informed, consenting patient and his or her care team.”

He stresses the importance of regulatory bodies acknowledging the diverse needs of patients, especially those dealing with conditions like Long COVID, to inform drug approval and usage strategies effectively.

Future Outlook and Invivyd’s Vision

Looking ahead, Mark Alia envisions Invivyd scaling its operations to address a broader spectrum of infectious diseases beyond COVID-19. His goal is to fill critical gaps in prevention and treatment, ensuring that advanced antibody therapies are accessible and affordable.

Mark Alia [13:26]: “Success would be building the power and the reach and the scale of what our technology can do to just protect as many people as we possibly can.”

Alia remains optimistic about the technological advancements in antibody therapies and their potential to complement vaccines, ultimately aiming to provide reliable alternatives for those with specific immunological needs.

Mark Alia [11:29]: “New medicines are obscure... we ought to be embracing them maximally.”

Conclusion

Erica Carbajal wraps up the conversation by highlighting the significance of expanding access to monoclonal antibody therapies and ensuring that patients with immunocompromising conditions have viable options. The episode underscores Invivyd’s pivotal role in advancing healthcare solutions during and beyond the pandemic.

Erica Carbajal [15:05]: “Such important ones around access, expanding access and just options for people with immunocompromising conditions...”

Mark Alia’s insights provide a compelling narrative on the intersection of personal experience, technological innovation, and strategic investment in the biotech sector, offering listeners a comprehensive understanding of Invivyd’s mission and the future of monoclonal antibody therapies.

For more insights and detailed discussions, tune into additional episodes of the Becker’s Healthcare Podcast by visiting their website.